In a phase I trial (clinicalTrials.gov (accessed on 20 October 2023) Id # NCT04676477), HER3-DXd combined with osimertinib was also administered in patients with locally advanced or metastatic EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.